Stefan K. Barta

Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.

J. Amengual, A. Sawas, J. Lue, 2024, Leukemia & lymphoma.

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.

Sonali M. Smith, R. Fisher, Y. Oki, 2019, Clinical lymphoma, myeloma & leukemia.